Zobrazit v EDS

Incidence of exudative age-related macular degeneration and treatment load under the Korean national health insurance system in 2010–2015

Uloženo v:
Podrobná bibliografie
Název: Incidence of exudative age-related macular degeneration and treatment load under the Korean national health insurance system in 2010–2015
Autoři: Tyler Hyungtaek Rim, Tae Keun Yoo, Seo Hee Kim, Dong Wook Kim, Sung Soo Kim
Přispěvatelé: Tyler Hyungtaek Rim, Tae Keun Yoo, Seo Hee Kim, Dong Wook Kim, Sung Soo Kim, Kim, Seo Hee
Zdroj: British Journal of Ophthalmology. 103:1361-1366
Informace o vydavateli: BMJ, 2018.
Rok vydání: 2018
Témata: Adult, Male, Vascular Endothelial Growth Factor A, retina, National Health Programs, National Health Programs / statistics & numerical data, Recombinant Fusion Proteins, Angiogenesis Inhibitors, Wet Macular Degeneration / drug therapy, 03 medical and health sciences, 0302 clinical medicine, Ranibizumab, Receptors, Republic of Korea, 80 and over, Wet Macular Degeneration / diagnosis, Humans, Ranibizumab / therapeutic use, age-related macular degeneration, Republic of Korea / epidemiology, Aged, Retrospective Studies, Aged, 80 and over, Recombinant Fusion Proteins / therapeutic use, Angiogenesis Inhibitors / therapeutic use, Incidence, Exudates and Transudates, Middle Aged, 3. Good health, Vascular Endothelial Growth Factor A / antagonists & inhibitors, Vascular Endothelial Growth Factor / therapeutic use, Receptors, Vascular Endothelial Growth Factor, Wet Macular Degeneration / epidemiology, Intravitreal Injections, Wet Macular Degeneration, Female, Follow-Up Studies
Popis: Background/AimThe aim of this study was to estimate the nationwide incidence of clinically diagnosed exudative age-related macular degeneration (AMD) and associated use of ranibizumab and aflibercept in South Korea.MethodsIn this retrospective, population-based cohort study, claims data for 2010–2015 were analysed in a randomly selected sample of 519 661 adults aged ≥40 years. The incidence per 10 000 person-years was estimated, along with the 95% CI. Incident exudative AMD was defined based on the registration code for rare intractable diseases. Use of ranibizumab and aflibercept and the incidence of exudative AMD were recorded.ResultsNine hundred and twelve patients were newly diagnosed with exudative AMD in 2010–2015. The 6-year incidence in the general population aged ≥40 years was 2.9 (95% CI 2.8 to 3.0) per 10 000 person-years. The incidence was highest in individuals aged 75–79 years (12.0, 95% CI 10.3 to 13.8). The incidence was higher in men than in women in all age groups. Six hundred and twenty-five (69%) of the 912 newly diagnosed patients started ranibizumab or aflibercept as a first-line treatment. The average number of injections administered was 6.1 (SD 3.9; minimum of 1 injection and maximum government-supported limit of 14) during 2010–2015; the number increased with increasing government funding support (from 5 to 10 and from 10 to 14 in 2013 and 2014, respectively).ConclusionsThis study describes the incidence of exudative AMD in South Korea and its treatment under the national health insurance system in this country. Its findings could be used for reference purposes and be useful when planning treatment for exudative AMD.
Druh dokumentu: Article
Jazyk: English
ISSN: 1468-2079
0007-1161
DOI: 10.1136/bjophthalmol-2018-312693
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/30573498
https://www.ncbi.nlm.nih.gov/pubmed/30573498
https://bjo.bmj.com/content/early/2018/12/19/bjophthalmol-2018-312693
https://bjo.bmj.com/content/103/10/1361
https://pubmed.ncbi.nlm.nih.gov/30573498/
https://bjo.bmj.com/content/bjophthalmol/early/2018/12/19/bjophthalmol-2018-312693.full.pdf
Rights: CC BY NC ND
Přístupové číslo: edsair.doi.dedup.....3c459a388490a0ca366f0b4b3a889368
Databáze: OpenAIRE
Popis
Abstrakt:Background/AimThe aim of this study was to estimate the nationwide incidence of clinically diagnosed exudative age-related macular degeneration (AMD) and associated use of ranibizumab and aflibercept in South Korea.MethodsIn this retrospective, population-based cohort study, claims data for 2010–2015 were analysed in a randomly selected sample of 519 661 adults aged ≥40 years. The incidence per 10 000 person-years was estimated, along with the 95% CI. Incident exudative AMD was defined based on the registration code for rare intractable diseases. Use of ranibizumab and aflibercept and the incidence of exudative AMD were recorded.ResultsNine hundred and twelve patients were newly diagnosed with exudative AMD in 2010–2015. The 6-year incidence in the general population aged ≥40 years was 2.9 (95% CI 2.8 to 3.0) per 10 000 person-years. The incidence was highest in individuals aged 75–79 years (12.0, 95% CI 10.3 to 13.8). The incidence was higher in men than in women in all age groups. Six hundred and twenty-five (69%) of the 912 newly diagnosed patients started ranibizumab or aflibercept as a first-line treatment. The average number of injections administered was 6.1 (SD 3.9; minimum of 1 injection and maximum government-supported limit of 14) during 2010–2015; the number increased with increasing government funding support (from 5 to 10 and from 10 to 14 in 2013 and 2014, respectively).ConclusionsThis study describes the incidence of exudative AMD in South Korea and its treatment under the national health insurance system in this country. Its findings could be used for reference purposes and be useful when planning treatment for exudative AMD.
ISSN:14682079
00071161
DOI:10.1136/bjophthalmol-2018-312693